After establishing the diagnosis of IBD, a therapeutic switch to another anti-TNF agent was performed in most cases with or without the association of azathioprine (AZA) or CS, with favorable evolution in all seven cases. The gene discussed is TNF; the disease is inflammatory bowel disease.